Cite
Checkmate: The drugs that have cancer on the run: Checkpoint inhibitors offer another approach for tackling advanced melanoma, but there are important adverse events to consider.
MLA
Goldinger, Simone, et al. “Checkmate: The Drugs That Have Cancer on the Run: Checkpoint Inhibitors Offer Another Approach for Tackling Advanced Melanoma, but There Are Important Adverse Events to Consider.” Australian Doctor, Aug. 2018, pp. 25–27. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=138042847&authtype=sso&custid=ns315887.
APA
Goldinger, S., Guitera, P., Fernández-Peñas, P., & Dummer, R. (2018). Checkmate: The drugs that have cancer on the run: Checkpoint inhibitors offer another approach for tackling advanced melanoma, but there are important adverse events to consider. Australian Doctor, 25–27.
Chicago
Goldinger, Simone, Pascale Guitera, Pablo Fernández-Peñas, and Reinhard Dummer. 2018. “Checkmate: The Drugs That Have Cancer on the Run: Checkpoint Inhibitors Offer Another Approach for Tackling Advanced Melanoma, but There Are Important Adverse Events to Consider.” Australian Doctor, August, 25–27. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=138042847&authtype=sso&custid=ns315887.